+

WO2002026737A8 - Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe - Google Patents

Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe

Info

Publication number
WO2002026737A8
WO2002026737A8 PCT/US2001/029896 US0129896W WO0226737A8 WO 2002026737 A8 WO2002026737 A8 WO 2002026737A8 US 0129896 W US0129896 W US 0129896W WO 0226737 A8 WO0226737 A8 WO 0226737A8
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolidine
pyridyl
ethoxy
benzyl
amino
Prior art date
Application number
PCT/US2001/029896
Other languages
English (en)
Other versions
WO2002026737A1 (fr
Inventor
Prabhakar Chebiyyam
Ramabhadra Sarma Mamillapalli
Vyas Krishnamurthi
Vishnuvardhan Reddy Seella
Om Reddy Gaddam
Original Assignee
Reddy Research Foundation
Cord Janet I
Prabhakar Chebiyyam
Ramabhadra Sarma Mamillapalli
Vyas Krishnamurthi
Vishnuvardhan Reddy Seella
Om Reddy Gaddam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0114196-1A priority Critical patent/BR0114196A/pt
Priority to EP01971336A priority patent/EP1322647A1/fr
Priority to AU2001291232A priority patent/AU2001291232B8/en
Priority to IL15503601A priority patent/IL155036A0/xx
Priority to MXPA03002580A priority patent/MXPA03002580A/es
Priority to KR10-2003-7004329A priority patent/KR20030082541A/ko
Priority to NZ525498A priority patent/NZ525498A/en
Priority to HU0301161A priority patent/HUP0301161A3/hu
Priority to PL01360661A priority patent/PL360661A1/xx
Priority to CA002426117A priority patent/CA2426117A1/fr
Priority to SK375-2003A priority patent/SK3752003A3/sk
Priority to AU9123201A priority patent/AU9123201A/xx
Application filed by Reddy Research Foundation, Cord Janet I, Prabhakar Chebiyyam, Ramabhadra Sarma Mamillapalli, Vyas Krishnamurthi, Vishnuvardhan Reddy Seella, Om Reddy Gaddam filed Critical Reddy Research Foundation
Priority to UA2003043901A priority patent/UA75370C2/uk
Priority to JP2002531121A priority patent/JP2004509961A/ja
Priority to US10/381,512 priority patent/US7241895B2/en
Publication of WO2002026737A1 publication Critical patent/WO2002026737A1/fr
Priority to IL155036A priority patent/IL155036A/en
Priority to NO20031356A priority patent/NO324968B1/no
Publication of WO2002026737A8 publication Critical patent/WO2002026737A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des nouvelles formes polymorphes/pseudo-polymorphes de 5-[4-[2[N-méthyl-N-(2-pyridyl)amino]éthoxy]benzyl] thiazolidine-2,4-dione maléate de formule (I). L'invention concerne également une composition pharmaceutique renfermant les nouvelles formes polymorphes ou un mélange de celles-ci et un adjuvant acceptable sur le plan pharmaceutique. Les formes polymorphes selon l'invention sont plus actives, comme agent anti-diabétique, que le 5-[4-[2-[N-(2-méthyl-N-(2-pyridyl)amino]éthoxy]benzyl] thiazolidine-2,4-dione maléate connu jusqu'à présent.
PCT/US2001/029896 2000-09-26 2001-09-25 Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe WO2002026737A1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
EP01971336A EP1322647A1 (fr) 2000-09-26 2001-09-25 Nouvelles formes polymorphes de 5- 4- 2- n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe
AU2001291232A AU2001291232B8 (en) 2000-09-26 2001-09-25 Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
IL15503601A IL155036A0 (en) 2000-09-26 2001-09-25 Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same
MXPA03002580A MXPA03002580A (es) 2000-09-26 2001-09-25 Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion.
KR10-2003-7004329A KR20030082541A (ko) 2000-09-26 2001-09-25 5-[4-[2-[엔-메틸-엔-(2-피리딜)아미노]에톡시]벤질]티아졸리딘 4-디온 말레이트의 신규의 다형상 및 그제조방법
NZ525498A NZ525498A (en) 2000-09-26 2001-09-25 Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
HU0301161A HUP0301161A3 (en) 2000-09-26 2001-09-25 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation
CA002426117A CA2426117A1 (fr) 2000-09-26 2001-09-25 Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe
PL01360661A PL360661A1 (en) 2000-09-26 2001-09-25 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
BR0114196-1A BR0114196A (pt) 2000-09-26 2001-09-25 Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
AU9123201A AU9123201A (en) 2000-09-26 2001-09-25 Novel polymorphic forms of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione maleate and process for their preparation
SK375-2003A SK3752003A3 (sk) 2000-09-26 2001-09-25 Polymorfné formy 5-[4[2-[N-metyl-N-(2- pyridyl)aminol]etoxy]benzyl]tiazolidín-2,4-dión maleátu a spôsob ich prípravy
UA2003043901A UA75370C2 (en) 2000-09-26 2001-09-25 Polymorphic forms of 5-[4-[2(n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2.4-dione maleate
JP2002531121A JP2004509961A (ja) 2000-09-26 2001-09-25 ５−［４−［２−［ｎ−メチル−ｎ−（２−ピリジル）アミノ］エトキシ］ベンジル］チアゾリジン−２，４−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法
US10/381,512 US7241895B2 (en) 2000-09-26 2001-09-25 Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
IL155036A IL155036A (en) 2000-09-26 2003-03-23 Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same
NO20031356A NO324968B1 (no) 2000-09-26 2003-03-25 Nye polymorfe former av 5-[4-[2-[N-metyl-N-(2-pyridyl]amino]etoksy]benzyl]tiazolidin-2,4-dionmaleat, fremgangsmate for fremstilling av samme, anvendelser av disse samt medikamenter inneholdende forbindelsene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN805/MAS/00 2000-09-26
IN805CH2000 2000-09-26

Publications (2)

Publication Number Publication Date
WO2002026737A1 WO2002026737A1 (fr) 2002-04-04
WO2002026737A8 true WO2002026737A8 (fr) 2003-11-06

Family

ID=29266775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029896 WO2002026737A1 (fr) 2000-09-26 2001-09-25 Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe

Country Status (15)

Country Link
EP (1) EP1322647A1 (fr)
JP (1) JP2004509961A (fr)
AU (1) AU9123201A (fr)
BR (1) BR0114196A (fr)
CA (1) CA2426117A1 (fr)
CZ (1) CZ2003864A3 (fr)
HU (1) HUP0301161A3 (fr)
IL (1) IL155036A0 (fr)
MX (1) MXPA03002580A (fr)
NO (1) NO324968B1 (fr)
NZ (1) NZ525498A (fr)
PL (1) PL360661A1 (fr)
SK (1) SK3752003A3 (fr)
WO (1) WO2002026737A1 (fr)
ZA (1) ZA200303223B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US7601841B2 (en) 2000-06-28 2009-10-13 Amgen Inc. Quinolinyl and benzothiazolyl modulators
US7626033B2 (en) 1999-06-30 2009-12-01 Amgen Inc. Compounds for the modulation of PPARγ activity
US9353080B2 (en) 2003-09-04 2016-05-31 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
AR023561A1 (es) 1999-04-23 2002-09-04 Smithkline Beecham Corp Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
DZ3155A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
WO2004062667A1 (fr) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Forme amorphe du maleate de rosiglitazone et procede de preparation
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (fr) * 2003-04-18 2004-11-03 CHEMI S.p.A. Formes polymorphes de maléate de rosiglitatone
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
EP1753759A2 (fr) * 2004-03-31 2007-02-21 Sandoz AG Nouveau co-precipite de rosiglitazone amorphe
JP2005350451A (ja) * 2004-05-11 2005-12-22 Santen Pharmaceut Co Ltd 角結膜障害治療剤
EP1757603A4 (fr) * 2004-05-11 2008-06-25 Santen Pharmaceutical Co Ltd Agent thérapeutique pour une affection de kératoconjonctivite
CZ296472B6 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (fr) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Procédé de préparation de formes galéniques solides de maléate de rosiglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (fr) * 1987-09-04 1998-05-20 Beecham Group Plc Thiazolidinédiones substituées
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CN1196730A (zh) * 1996-06-19 1998-10-21 雷迪博士研究基金会 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法
JP2000514041A (ja) * 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
DZ3155A1 (fr) * 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
AR023561A1 (es) * 1999-04-23 2002-09-04 Smithkline Beecham Corp Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7626033B2 (en) 1999-06-30 2009-12-01 Amgen Inc. Compounds for the modulation of PPARγ activity
US7601841B2 (en) 2000-06-28 2009-10-13 Amgen Inc. Quinolinyl and benzothiazolyl modulators
US9353080B2 (en) 2003-09-04 2016-05-31 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9371309B2 (en) 2003-09-04 2016-06-21 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound

Also Published As

Publication number Publication date
WO2002026737A1 (fr) 2002-04-04
SK3752003A3 (sk) 2005-03-04
JP2004509961A (ja) 2004-04-02
EP1322647A1 (fr) 2003-07-02
ZA200303223B (en) 2004-07-26
HUP0301161A3 (en) 2005-04-28
CA2426117A1 (fr) 2002-04-04
MXPA03002580A (es) 2003-10-15
BR0114196A (pt) 2003-07-22
NZ525498A (en) 2004-11-26
IL155036A0 (en) 2003-10-31
CZ2003864A3 (cs) 2004-01-14
NO324968B1 (no) 2008-01-14
AU9123201A (en) 2002-04-08
NO20031356D0 (no) 2003-03-25
PL360661A1 (en) 2004-09-20
HUP0301161A2 (hu) 2003-11-28
NO20031356L (no) 2003-05-26

Similar Documents

Publication Publication Date Title
WO2002026737A8 (fr) Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe
HUP0300158A3 (en) Hydrochloride salts of-5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for their production and pharmaceutical compositions containing them
EP1078923A3 (fr) Procédé de préparation de dérivés de benzothiophène
HUP0200931A3 (en) Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, process for preparation thereof and its pharmaceutical use
IL136424A (en) Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, and pharmaceutical compositions comprising it
IL136381A (en) Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy] benzyl] thiazolidine-2,4-dione maleic acid salt, its preparation and pharmaceutical compositions comprising it
CA2197272A1 (fr) Promedicament: 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chloro-1,3-dihydro-2h-indol-2-one
WO2002028857A8 (fr) Polymorphes de chlorhydrates de pioglitazone et leur utilisation en tant qu'antidiabetiques
WO2000063205A3 (fr) Nouveau compose pharmaceutique
WO2000063206A3 (fr) Nouvelle substance pharmaceutique
AP1814A (en) Tartrate salts of thiazolidinedione derivative.
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
PT1349855E (pt) Sal misilato de 5-{4-[2-(n-metil-n-(2-piridil)amino)etoxi]benzil}tiazolidino-2, 4-diona
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
AU2001284285A1 (en) A thiazolidinedione derivative and its use as antidiabetic
AU2001284274A1 (en) A thiazolidinedione derivative and its use as antidiabetic
WO2005021542A3 (fr) Procede pour la preparation de pioglitazone
AP1785A (en) Tartrate salt of thiazolidinedione derivative.
AP2003002737A0 (en) Tartrate salts of thiazolidinedione derivatives
HUP0301188A3 (en) Sodium salts of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, process for their preparation and pharmaceutical compositions containing them
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
AP1813A (en) Tartrate salts of thiazolidinedione derivative.
AU2002343050A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 155036

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002580

Country of ref document: MX

Ref document number: 3752003

Country of ref document: SK

Ref document number: PV2003-864

Country of ref document: CZ

Ref document number: 2426117

Country of ref document: CA

Ref document number: 1020037004329

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002531121

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 018174302

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001971336

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200303223

Country of ref document: ZA

Ref document number: 525498

Country of ref document: NZ

Ref document number: 2001291232

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2003112226

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 2001971336

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037004329

Country of ref document: KR

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 14/2002 UNDER (71) REPLACE "REDDY?S RESEARCH FOUNDATION [IN/IN]" BY "DR. REDDY?S RESEARCH FOUNDATION [IN/IN]"

Free format text: IN PCT GAZETTE 14/2002 UNDER (71) REPLACE "REDDY?S RESEARCH FOUNDATION [IN/IN]" BY "DR. REDDY?S RESEARCH FOUNDATION [IN/IN]"

WWE Wipo information: entry into national phase

Ref document number: 10381512

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-864

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 525498

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 525498

Country of ref document: NZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载